Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

koers MDxHealth naar 15,25 en later naar 47 euro

1.073 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 54 »» | Laatste | Omlaag ↓
  1. [verwijderd] 19 juli 2016 16:26
    quote:

    inspirator schreef op 4 mei 2015 22:33:

    MDXH should be worth at least 15.25 Euros a share compared to the current share price of 5 Euros a share and maybe much more over time. Biotech and smaller healthcare companies in Europe are often cheaper than their US equivalents.

    seekingalpha.com/article/3118556-mdxh...

    Morgen spin-off na publicatie Q1 cijfers MDxHealth en wederom publiciteit voor MDxHealth
    Er broeit iets: vandaag koersverschil hoog/laag al 10%.
  2. [verwijderd] 20 juli 2016 17:16
    The key players operating in this market are Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.).

    The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Factors such as the growing incidence of cancer, benefits of liquid biopsy over solid tumor biopsy, technological advancements, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market. However, the unclear regulatory

    In 2016, North America is expected to command the largest share of the liquid biopsy market. Factors such as easy accessibility and high adoption of advanced diagnostic technologies, such as PCR and NGS, among healthcare professionals; increasing prevalence of cancer in the U.S. and Canada; and continuous technological advancements in liquid biopsy are responsible for the large share of North America in the liquid biopsy market. However, the Asia-Pacific liquid biopsy market is estimated to grow at the highest CAGR during the forecast period, primarily due to the increasing focus of players on this region.

    www.marketsandmarkets.com/Market-Repo...
  3. [verwijderd] 22 juli 2016 10:19
    Dit draadje is onzin, kul. Beter sluiten en de zaken centraal bespreken. Waar of niet peebee? Dit is gewoon een beetje fun. Inspirator weet dat ook wel. Over een paar weken gaat ie weer een ander fonds promoten. Name het €100 draadje van Galapagos. Stille dood gestorven. Duurt meneer te lang...centjes zijn op of weet ik veel.
  4. [verwijderd] 23 juli 2016 01:07
    Eerst de koers nog effe drukken en dan bam overnamebod op MdxHealth.

    Voor een dollar een steeds voordeligere overname.

    MDXH should be worth at least 15.25 Euros a share compared to the current share price of 5 Euros a share and maybe much more over time. Biotech and smaller healthcare companies in Europe are often cheaper than their US equivalents.

1.073 Posts
Pagina: «« 1 ... 21 22 23 24 25 ... 54 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.